Overview

Food Study of Glimepiride Tablets 1 mg to Amaryl® Tablets 1 mg

Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the bioequivalence of Mylan's glimepiride 1 mg tablets to Aventis Amaryl® 1 mg tablets following a single, oral 1 mg (1 x 1 mg) dose administered under fed conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Mylan Pharmaceuticals
Treatments:
Glimepiride